Hepatitis B functional cure with bepirovirsen held in 90% to 92% of responders 48 weeks after stopping all therapy, per data at The Liver Meeting 2026.
Publication|Articles|July 27, 2026
- August 2026
- Volume 32
- Issue Spec 9
The Promise and Politics of Creating mRNA Vaccines in Cancer
Author(s)Ryan Flinn
Our August cover story from Evidence-Based Oncology.
Advertisement
Advertisement
In June, Moderna and Merck reported clinical trial follow-up results showing that their combination mRNA cancer vaccine and immunotherapy reduced the risk of melanoma recurrence in high-risk patients by nearly half over 5 years.1
Related to this article
GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non-drug care up front.
Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.
Resmetirom real-world data at The Liver Meeting 2026 show 12-month gains in liver stiffness, fat, and enzymes among patients with MASH in 3 US data sets.
A study of 132 patients with AML given venetoclax-based therapy, 10 profiled by single-cell sequencing, linked immune features to treatment response.
This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.
Greater 340B activity—measured by county-level hospital child sites and contract pharmacy arrangements—was associated with significantly higher county-level total and out-of-pocket health care spending.
Clinicians at Population Health Roundtables shared obesity care innovations, from pharmacist-led models to same-day liver screening
Advertisement
Advertisement